Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to achieve revenue of 145.5-147.5 billion yuan for 2025, representing a year-over-year growth of 9% to 11%. The net profit attributable to shareholders is projected to be between 10.3-11.7 billion yuan, indicating a significant year-over-year increase of 129% to 160% [4] - The company has seen a recovery in procurement demand since 2025, with most product prices reaching a bottom. The global pesticide market is gradually normalizing, leading to substantial improvements in the company's performance [6] - The company is enhancing its global marketing network, and the value of its overseas formulation business needs to be reassessed. The cancellation of certain export VAT rebates is expected to create a "rush to export" scenario before April 1, 2026, which may boost demand for various products [6] Financial Data and Profit Forecast - The total revenue for 2025 is estimated at 14,645 million yuan, with a year-over-year growth rate of 10.1%. The net profit attributable to shareholders is forecasted to be 1,148 million yuan, reflecting a year-over-year growth of 155.1% [5] - The company’s gross margin is expected to improve, with projections of 21.9% for 2025 and 22.6% for 2026. The return on equity (ROE) is anticipated to be 14.8% in 2025 and 15.8% in 2026 [5] - The current market capitalization corresponds to a price-to-earnings (PE) ratio of 19 for 2025, 16 for 2026, and 13 for 2027, indicating a favorable valuation as the industry recovers [6]
润丰股份（301035）：全年业绩大幅改善，制剂出海价值亟需重估